Perucca, Emilio http://orcid.org/0000-0001-8703-223X
White, H. Steve http://orcid.org/0000-0003-4550-4408
Bialer, Meir http://orcid.org/0000-0003-2046-4171
Funding for this research was provided by:
University of Melbourne
Article History
Accepted: 29 June 2023
First Online: 21 August 2023
Declarations
:
: Open Access funding enabled and organized by CAUL and its Member Institutions. The preparation of this article was not supported by any funding source.
: Emilio Perucca received speaker fees or fees from consulting or participation in advisory boards/data safety monitoring boards from Angelini, Arvelle, Biopas, Eisai, GW Pharma, Janssen, PMI Life Sciences, Sanofi group of companies, Shackelford Pharma, SKL Life Science, Sun Pharma, Takeda, UCB Pharma, Xenon Pharma and Zogenix, and royalties from Wiley, Elsevier and Wolters Kluwers, all outside the submitted work. Meir Bialer received consultancy fees from Boehringer Ingelheim, Clexio Therapeutics, Guidepoint, Pharma2B, Shackelford Pharma and US WorldMeds. H. Steve White has received grant funding from UCB Pharma and Eisai Pharmaceuticals, Neurelis, Inc. and consultant fees from GW Pharmaceuticals, Neurelis, Inc., Takeda Pharmaceuticals, SK Life Sciences and Jazz Pharmaceuticals and speaker honoraria from SK Pharmaceuticals, Takeda Pharmaceuticals and UCB Pharma.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: This article is an invited review. All authors contributed to the literature search. EP and MB produced the original draft. HSW revised critically the sections related to the mechanisms of action and pharmacological properties of the compounds listed, and contributed to the drafting of Sect.InternalRef removed. All authors participated equally in the finalisation of the manuscript and they all met ICMJE criteria for authorship. All authors have read and approved the final submitted manuscript, and agree to be accountable for the work.